SCHEMBL8512776

SCHEMBL8512776

[SiH3]O[SiH2]CCOCC1CO1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1502161 0.89 TSHR (0.61) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL4925410 0.80 TSHR (0.54) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL12215241 0.77 SMN1; SMN2 (0.53) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL2231944 0.76 TSHR (0.48) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL27840849 0.76 TSHR (0.48) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL7941221 0.75 TSHR (0.53) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL14582472 0.75
SCHEMBL16684221 0.75 TSHR (0.79) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL22418810 0.75 TSHR (0.79) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1
SCHEMBL17197994 0.75 TSHR (0.79) TSHRSMN1; SMN2ALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3021948-B1 OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS OREAL (FR) 2019-08-21 EP disclosed
WO-2016116475-A1 O/O EMULSION CONTAINING MICROPARTICLES WITH A BREAK IN THE CURVATURED PART, COMPOSITIONS COMPRISING SAME AND USE OF MICROPARTICLES FOR STABILIZING THE O/O EMULSIONS L'OREAL (FR) 2016-07-28 WO disclosed
US-20160158118-A1 OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS L'OREAL (FR) 2016-06-09 US disclosed
EP-3021948-A1 OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS L'OREAL (FR) 2016-05-25 EP disclosed
WO-2015008263-A1 OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS L'OREAL (FR) 2015-01-22 WO disclosed
US-8802272-B2 Method of producing polyolefin microporous membrane and separator for lithium ion battery TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) 2014-08-12 US disclosed
US-20130252067-A1 METHOD OF PRODUCING POLYOLEFIN MICROPOROUS MEMBRANE AND SEPARATOR FOR LITHIUM ION BATTERY TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) 2013-09-26 US disclosed
EP-2469623-A1 Polyolefin microporous membrane and separator for lithium ion battery Takemoto Yushi Kabushiki Kaisha (JP) 2012-06-27 EP disclosed
US-20120135289-A1 POLYOLEFIN MICROPOROUS MEMBRANE AND SEPARATOR FOR LITHIUM ION BATTERY NODA IPPEI (JP) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158118-A1 OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS NONO, SQLE, PFN1 TSHR 1277/4885SMN1; SMN2 2743/4885ALDH1A1 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.